

VOLUME 272 • NUMBER 1 • JANUARY 1995

JPETAB 272 (1) 1-475 (1995)

ISSN 0022-3565

272

JOL

The Journal of

PHARMACOLOGY

AND EXPERIMENTAL THERAPEUTICS

*A Publication of The American Society
for Pharmacology and Experimental Therapeutics
Founded by John J. Abel—1909*

JAN 18 1995

1995

Edited for the Society by John A. Harvey

MARIE SMITH SCHWARTZ MEDICAL LIBRARY
BROOKDALE HOSPITAL MEDICAL CENTER



Published by Williams & Wilkins



EXPLORATION VEHICLE.

There are no road maps for understanding the efficacy, toxicity and side effects of newly discovered compounds. In the complex biological landscape, conflicting effects in different organs and tissues often obscure the path to success.

But there is a way to chart a course to complete understanding when exploring new pharmacological terrain in vivo. ALZET® osmotic pumps.

These miniature, implantable pumps have proven effective for continuous delivery of a wide variety of agents in mice and rats. They maintain effective levels of short half-life compounds in plasma and tissues and can be used with a catheter to target specific areas.

So, if you're preparing to enter new research territory, find out how ALZET pumps can help you get where you want to go.

alzet
OSMOTIC PUMPS

Call ALZA Corporation at 800-692-2990 or (415) 962-4128 or fax 415-962-2488. Specify the agent of interest or the region you wish to explore. We'll send you a list of references and technical information that will prove invaluable on your next expedition.

COPYRIGHT © 1995 BY THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

INFORMATION FOR SUBSCRIBERS

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (ISSN 0022-3565) is an official publication of The American Society for Pharmacology and Experimental Therapeutics and is published by Williams & Wilkins, 428 E. Preston St., Baltimore, MD 21202-3993. Second class postage paid at Baltimore, MD and at additional mailing offices. **POSTMASTER:** Send address changes to THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 428 E. Preston St., Baltimore, MD 21202-3993.

Frequency: *Monthly:* Four volumes a year beginning in January, April, July, and October.

Correspondence concerning business matters should be addressed to: Customer Service, Subscriptions, Williams & Wilkins, 428 E. Preston Street, Baltimore, MD 21202-3993. Telephone 1-(800) 638-6423 from anywhere in the U.S. and Canada. From other countries, call (410) 528-8555. Fax: (410) 528-8596.

Correspondence regarding editorial matters should be addressed to the Editor: John A. Harvey, Ph.D., Chief, Division of Behavioral Neurobiology, Department of Pharmacology, The Medical College of PA at EPPI, 3200 Henry Avenue—Suite 129, Philadelphia, PA 19129. Telephone: (215) 842-4061 Fax: (215) 843-0690.

For information on Society membership, contact: The American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814. Telephone (301) 530-7060 Fax: (301) 530-7061.

Instructions to Authors appears in the first issue of each volume (January, April, July, October).

Annual Subscription Rates: U.S.: *Personal* \$190.00; *Institutional* \$340.00; *Single copy* \$30.00. **Outside the U.S., except for Japan:** *Personal* \$255.00; *Institutional* \$405.00; *Single copy* \$35.00.

Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial and private institutions and organizations.

For Japanese rates, please contact: Igaku-Shoin MYW Ltd., 3-23-14 Hongo, Bunkyo-Ku, Tokyo 113, JAPAN. Telephone: (03) 5689-5400 or 5401. Fax: (03) 5689-5402.

PRICES ARE SUBJECT TO CHANGE.

The GST number for Canadian subscribers is 123394371. Country of origin USA.

New subscriptions received before May 1st of each year will begin with the first issue of the year. Subscriptions received between May 1st and October 31st will start with the mid-year issue (July). Subscriptions received after October 31st will start with the first issue of the following year. Subscriptions may start with any current volume's issue upon request.

Renewals should be done *promptly* to avoid a break in

journal delivery. The Publisher cannot guarantee to supply back issues on late renewals.

Change of address: The publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicate copies may be obtained, if available, from the Publisher at the regular price of a single issue. Send address changes to THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 428 East Preston Street, Baltimore, MD 21202-3993. **If a member**, please contact the Society with your change.

Reprints of individual articles are available only from the authors.

Reprints in large quantities, for commercial or academic use, may be purchased from the Publisher. For information and prices call (410) 528-4292.

Microfilm and Microfiche: Prices are available upon request. Microfilm editions may be ordered from Williams & Wilkins.

The Journal subscription list is available for rental on a controlled basis from Williams & Wilkins. All promotional literature must be approved in advance.

Disclaimer: The statements and opinions contained in the articles of THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics or Williams & Wilkins. The appearance of advertisements in the Journal is not a warranty, endorsement or approval of the products or safety. The American Society for Pharmacology and Experimental Therapeutics and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Volume indices appear in the March, June, September, and December issues.

Indexing/Abstracting Services: The Journal is currently included by the following services in print and/or electronic format: *Index Medicus*, *Current Contents (Life Sciences, Science Citation Index, Research Alert [personalized search service], ISI/BioMed [on-line database], Excerpta Medica*, and *Biosciences Information Service*, and *Reference Update/Research Information Systems*.

Copyright Information: THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. No portion(s) of the work(s) may be reproduced without written consent from Williams & Wilkins. Permission to reproduce copies of articles for non-commercial use may be obtained from the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (508) 750-8400, with a fee of \$3.00 per copy.

Copyright © 1995 by the American Society of Pharmacology and Experimental Therapeutics.

AUTHOR INDEX

- Abdeen, O. A., 282
 Aiba, T., 94
 Almawi, W., 399
 Anderson, P. S., 20
 Aposhian, H. V., 264
 Aposhian, M. M., 264
 Arendt, R. M., 1
 Ator, N. A., 100
 Autore, G., 469
 Bach, T. J., 452
 Bailey, D. S., 134
 Baron, J. A., 151
 Bekavac, I., 333
 Benincosa, L. J., 248
 Bergsbaken, C., 322
 Bertolino, M., 300
 Bourrié, B., 224
 Braeckman, R. A., 119
 Brinck-Johnsen, T., 151
 Burnett, J. P., 38
 Burrier, R. E., 156
 Bye, L. S., 423
 Campbell, S., 134
 Capasso, F., 469
 Caruncho, H. J., 438
 Casellas, P., 224
 Chakder, S., 385
 Chan, K., 417
 Chang, C. T.-C., 20
 Chang, R. L., 197
 Chaplan, S. R., 207
 Chaudhry, A., 446
 Chemtob, S., 15
 Cherwinski, H. M., 460
 Claro, E., 77
 Cohen, M. L., 143, 446
 Comi, R. J., 151
 Conney, A. H., 197
 Cook, J. J., 20
 Costa, E., 300, 438
 Cox, D. A., 143
 Coy, D. H., 371
 Crabbe, J., 275
 Cryns, V., 151
 Cushing, D. J., 446
 Dart, R. C., 264
 Davis, H. R., Jr., 156
 Derocq, J.-M., 224
 Desai, M. A., 38
 Devens, B., 460
 Diaz Gama, J. H., 264
 DiBella, M., 300
 Di Carlo, G., 469
 Dučić, I., 438
 Duggan, M. E., 20
 Echeverria, D., 264
 Egbertson, M. S., 20
 Fabry, S., 399
 Fermi, B., 184
 Fidock, M. D., 134
 Flores-Murrieta, F. J., 352
 Fournié-Zaluski, M.-C., 343
 Fraser, L., 392
 Frederick, D., 429
 Friedman, P. A., 20
 Furness, L. M., 134
 Furukawa, T., 70
 Gancher, S., 275
 Garland, A., 275
 Gibbons, J. A., 119
 Gonzalez-Ramirez, D., 264
 Gould, R. J., 20
 Granados-Soto, V., 352
 Granneman, J. G., 446
 Grant, S. K., 452
 Grevelink, S. A., 33
 Gu, Z.-F., 371
 Guglietta, A., 417
 Guidotti, A., 300
 Halczenko, W., 20
 Hannon, E. R., 119
 Hartman, G. D., 20
 Heucke, L., 1
 Hewett, J. A., 53
 Holahan, M. A., 20
 Holsapple, M. P., 407
 Hom, G. J., 452
 Hong, E., 352
 Hoos, L. M., 156
 Hori, R., 63
 Hsu, P., 44
 Hurlbut, K. M., 264
 Hutchinson, N. I., 452
 Ikeda, M., 177
 Inui, K.-i., 63
 Izzo, A. A., 469
 Jensen, R. T., 371
 Jeong, T. C., 407
 Johnston, G. I., 134
 Jordan, S. D., 407
 Junco-Munoz, P., 264
 Kalman, J. M., 85
 Kaminski, E. J., 407
 Kaneko, T., 357
 Keresztes, S., 399
 Kihara, T., 177
 Koizumi, T., 94
 Kong, H., 423
 Kosten, T. R., 231
 Kung, H. F., 429
 Kung, M.-P., 429
 Kuratani, K., 256
 Kushiku, K., 70
 Kuwahara, T., 70
 Laboulandine, I., 343
 Larkin, S. W., 392
 Laswell, W. L., 20
 Law, P. Y., 322
 Le, H. T., 364
 Lea, E., 275
 Lech, J., 197
 Lee, Y. W., 207
 Leffler, C. W., 44
 Le Fur, G., 224
 Lerner, E. A., 33
 Lesch, C. A., 417
 Li, D.-Y., 15
 Lipman, M., 399
 Little, H. J., 112
 Liu, J., 423
 López-Muñoz, F. J., 352
 Loscalzo, J., 33
 Luo, Z.-P., 119
 Lynch, J. J., Jr., 20
 Lynch, R. J., 20
 MacIntyre, D. E., 452
 Madwed, J. B., 126
 Maeda, N., 256
 Maiello, F. M., 469
 Maiorino, R. M., 264
 Manno, P. D., 20
 Mascolo, N., 469
 Matsuoka, N., 256
 Matulka, R. A., 407
 McCarley, D., 460
 McGregor, D. G., 156
 Mellott, M. J., 20
 Mercer, N. G., 151
 Mestek, A., 423
 Michel, J.-B., 343
 Morris, M. E., 248
 Moscovitch-Lopatin, M., 399
 Mosley, M. J., 134
 Movahedi, H., 364
 Mu, M., 429
 Nakashima, M., 379
 Nattel, S., 184
 Ohjimi, H., 70
 Ohkubo, Y., 256
 Okabe, S., 357
 Oliveto, A. H., 231
 Ornstein, P. L., 38
 Osborne, J., 33
 Page, S. O., 134
 Palkowitz, A. D., 446
 Parfenova, H., 44
 Parry-Smith, D. J., 134
 Patrick, G. S., 310
 Peppercorn, M. A., 399
 Peter, B., 134
 Pham, I., 343
 Picatoste, F., 77
 Pitts, D. K., 164
 Plasse, A., 1
 Pillana, R., 417
 Pogrel, J. W., 207
 Power, J. M., 85
 Pradhan, T. K., 371
 Printz, M. P., 282
 Purdy, R. E., 364
 Ramjit, D. R., 20
 Ransom, J. T., 460
 Rattan, S., 385
 Raynor, K., 423
 Reisine, T., 423
 Rinken, A., 8
 Ripley, T. L., 112
 Roques, B.-P., 343
 Rosen, M. I., 231
 Rosen, R. T., 197
 Roth, R. A., 53
 Sagawa, K., 248
 Sakurai, Y., 94
 Sanchez, B., 417
 Sannerud, C. A., 100
 Sarri, E., 77
 Schachter, J. B., 215
 Schatzman, R., 460
 Schenck, K. W., 446
 Schmoeckel, M., 1
 Schoepp, D. D., 38
 Schwinn, D. A., 134
 Ségui, M., 224
 Shafer, J. A., 20
 Showell, H. J., 392
 Sitko, G. R., 20
 Smith, A. A., 156
 Smith, F. L., 290
 Spangford, H. M., 364
 Stabilito, I. I., 20
 Stanulis, E. D., 407
 Stevens, C., 399
 Stevens, D. L., 290
 Stranieri, M. T., 20
 Strom, T. B., 399
 Suchar, L. A., 197
 Swaan, P. W., 242
 Takano, M., 63
 Takehara, K., 357
 Takeuchi, K., 357
 Taylor, B. K., 282
 Thomas, C., 310
 Thompson, D. M., 300
 Tian, M., 423
 Tomita, Y., 63
 Tonkin, A. M., 85
 Tsukada, S., 94
 Tukker, J. J., 242
 Uzunov, D., 300
 Vanhoutte, P. M., 379
 Varma, D. R., 15
 Vassallo, L. M., 20
 Veljaca, M., 417
 Vera, W. G., 343
 Vicini, S., 438
 Wang, L., 164
 Wang, Z., 184
 Warren, J. B., 392
 Waterhouse, B. D., 333
 Welch, S. P., 310
 Weldon, S. M., 126
 Werdan, K., 1
 Wilbert-Lampen, U., 1
 Williams, T. J., 392
 Wilson, K. H., 134
 Winquist, R. J., 126
 Wolfe, B. B., 215

Wolfe, G., 452
Woods, J. S., 264
Woods, S. W., 231
Woodward, W., 275
Worman, N. P., 134

Xu, Z., 264
Yaksh, T. L., 207
Yamada, H., 70
Yamaguchi, I., 256
Yamazaki, M., 256

Yasuhara, M., 63
Young, J. D., 119
Youngblood, K. L., 282
Yu, L., 423
Zhang, G., 20

Zhu, W. J., 438
Zhuang, Z.-P., 429
Zilli, D. L., 156
Zivkovic, I., 300
Zuniga-Charles, M., 264

Notice to Contributors (Revised July 1, 1994)

Scope of Submitted Manuscripts

The Journal invites for review original papers dealing with interactions of chemicals with biological systems. Any aspect of pharmacology and therapeutics is included, but descriptive case reports without dose response or mechanism studies are not accepted. Manuscripts dealing primarily with new methods will be reviewed only if data are presented showing new or more reliable pharmacological information has been obtained by use of the methods.

Submission of Manuscripts

Submit four copies of manuscript to **Dr. John A. Harvey, Editor in Chief, Journal of Pharmacology and Experimental Therapeutics, Department of Pharmacology, Suite 129, The Medical College of Pennsylvania at EPPI, 3200 Henry Avenue, Philadelphia, PA 19129**, accompanied by a check or purchase order for **\$40.00 manuscript handling fee** (in U.S. funds drawn on a U.S. bank payable to ASPET). If submission of the manuscript handling fee entails personal financial hardship to the author, the fee will be waived. In that event the authors should submit a request for waiver of the fee at the time the manuscript is submitted. Only one copy of rejected manuscripts will be returned. Extra copies of figures will not be returned unless specifically requested at the time the manuscript is submitted.

Manuscripts should be typewritten and double spaced in the English language using one side only of approximately 21.6 by 28 cm paper. One original drawing or photograph of each line figure and four (4) clear copies and/or 4 original drawings or photographs of each halftone figure are required. Pages should not be stapled together.

Authors submitting a manuscript do so with the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. Reasonable requests by authors for permission to reproduce their contributions to the Journal will not be refused. It will be necessary for all authors to sign an assignment of copyright form which will be mailed from the Editorial Office on acceptance of the manuscript. The only exceptions will be manuscripts on work performed by employees of the U.S. Federal Government.

Cover Letter

Each manuscript must be accompanied by a written statement signed by one author: "The undersigned author affirms that the manuscript (title of article) and the data it contains are original, are not under consideration by another journal, and have not been published previously. The studies reported in this manuscript have been carried out in accordance with the Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institute of Health". Authors should also indicate in the cover letter the field of pharmacology to which the research applies.

Organization of the Manuscript

In most cases manuscripts should contain the following sections in the order listed; each section should begin on a new page and all pages should be numbered consecutively.

1. Title page. This should contain the complete title of the manuscript, the names of all authors, and the laboratory of origin. Support for the research should be indicated as a numbered footnote to the title and included with other footnotes on a separate page following the reference section.

2. Running title page. a) A running title: should be included at the top of this page and should contain no more than 35 spaces, including punctuation. It should convey the sense of the full title. Commonly used abbreviations (such as "ATP," "ACh," etc.) may be used in the running title. b) Corresponding author: this page should also contain the name, address, telephone and fax number of the person to whom all correspondence should be sent. c) A list of abbreviations used in the paper should also appear on this page. Additionally, each abbreviation should be defined the first time it is used in the text.

3. Abstract. The abstract should present in a concise form the purpose, the general methods, the findings, and the conclusions of the manuscript. Abstracts should be limited to 200

words; abstracts of more than 250 words will not be accepted.

4. Introduction. This section should not be labeled, but should begin on a new page. It should contain a clear statement of the aims of the reported work or of the hypotheses which the work was designed to test. A brief account of the background of the reported work may also be given in this section.

5. Methods. This section should contain explicit, concise descriptions of all new methods or procedures employed. Modifications of previously published methods should be described. Commonly used methods require only a citation of the original source. When methods are described, the description should be such as to enable the reader to judge their accuracy, reproducibility and reliability and to repeat the experiment. Very extended descriptions of methods may be submitted for deposit with the American Society for Information Science National Auxiliary Publications Service (NAPS) c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10017. A text reference or footnote stating that the full description is available from NAPS permits interested readers to obtain the information and does not occupy an inordinate amount of Journal space. There is a nominal charge to authors for this procedure; those who request the complete information from NAPS pay a small fee.

6. Results. This section ordinarily contains the experimental data to be presented, but not extended discussions of their significance. Results should usually be presented in graphic or tabular form, rather than discursively. Graphic presentation of data is often preferred but there should not be duplication in text, tables and figures. Sufficient data must be given to allow readers to judge the variability and reliability of the results. Statistical tests used and the data analyzed should be explained so that the findings can be interpreted and evaluated.

7. Discussion. This section should present conclusions to be drawn from the results. Speculative discussion is not discouraged, but the speculation should be based on the data presented and identified as such. The discussion should be as concise as possible, within the limits of the ideas which the authors wish to propose and adequate discussion of related work by others.

8. Acknowledgments. This section should begin on a separate page, have a separate heading, and be placed at the end of the text of the manuscript. Gifts and assistance can be acknowledged here but, financial support should appear in a footnote to the title.

9. References. In text citations give the author's name and the year of publication (e.g., McCarthy, 1952; Ruth and Gehrig, 1929). With more than two authors, the text citation should contain the name of the first author, followed by "et al.," and the date (e.g., Kennedy et al., 1960). In the list of references, entries should be arranged alphabetically by author and not numbered. All authors' names should be given. If reference is made to more than one publication by the same authors in the same year, suffixes (a, b, c, etc.) should be added to the year in the text citation and in the list of references.

The list of references should contain, in sequence, the following information: authors' names and initials, title of the cited article, title of the journal in which it appeared, volume number of the journal, inclusive pagination and year of publication. Abbreviations for journals should conform to the Biosis List of Serials (BioSciences Information Services of Biological Abstracts, Philadelphia, PA 19103). Citations of personal communications, unpublished observations, and papers submitted for publication should be given in parentheses at the appropriate place in the text, not in the list of references. A paper may not be cited as "in press" unless it has been accepted for publication. In such cases the name of the journal must be given.

Examples of references to books, chapters and journal articles follow:

- Bruce, M. S.: The anxiogenic effects of caffeine. *Postgrad. Med. J.* 66: 18-24, 1990.
Griffiths, R. R., Bigelow, G. E. and Liebson, I. A.: Human Coffee drinking: Reinforcing and physical dependence producing effects of caffeine. *J. Pharmacol. Exp. Ther.* 239: 416-425, 1986.
Tallarida, R. J. and Murray, R. B.: *Manual of Pharmacologic*

Calculations with Computer Programs. Springer-Verlag, New York, 1987.

Young, A. M. and Sannerud, C. A.: Tolerance to drug discriminative stimuli. In *Psychoactive Drugs: Tolerance and Sensitization*, ed. by A. J. Goudie and M. W. Emmett-Oglesby, pp. 221-270, Humana Press, Clifton, NJ, 1989.

No more than four references should be cited in support of any given point. The authors are responsible for accuracy of such citations and are urged to take the utmost care in proofreading citations and the reference list.

10. Footnotes. All footnotes to the title, authors' names or text should be indicated by arabic numeral superscripts, not by letters or other symbols. The footnotes should be typed in sequence on a separate page, not a text page. Footnotes to tables are discussed under Tables, below.

11. Tables. Each table should be on a separate page. Tables should be numbered consecutively with arabic numerals, and should be designed to fit the column or page size of the Journal. A brief descriptive title should be given at the top of each table. The table number should be given in capital letters, the title in boldface upper and lower case letters (e.g., TABLE 3. **Uptake of labeled drug by rat liver slices**). The footnotes to the tables should be referenced by italicized lower case superscript letters (a, b, c, etc.) and should appear beneath the table involved, not on a separate page of the manuscript. Extensive tabular material not absolutely essential to the manuscript will be accepted for deposit with the ASIS/NAPS (see "Methods," above). In such instances a footnote in the published paper will refer the interested readers to NAPS from which copies may be obtained. Note *Statistics* below for expressions of probability.

12. Legends for figures. These should be numbered consecutively in arabic numerals and should appear on a separate page of the manuscript. Legends should explain the figures in sufficient detail so that frequent referral to the text is unnecessary, but efforts should be made to avoid unnecessary length. Abbreviations in the legends should conform to those in the text (see "Abbreviations," below).

13. Figures. Illustrations should be submitted as unmounted glossy prints, or laser jet quality figures, preferably reduced to single column size (approximately 3½ inches in width) to permit reproduction without further reduction. Otherwise, prints should be no larger than 8 by 10 inches and clear enough to permit reproduction without retouching after reduction. The author's name and address and the number of the figure should be placed on the back of each print. A typed label is usually most satisfactory. Ball type pen should not be used. Note *Statistics* below for expression of probability. Uniform symbolism should be used for all illustrations in a manuscript. Symbols, numbers, and letters in the illustrations must be at least 1.5mm in height after reduction to single column size. The title of each figure should appear in the legend rather than on the figure itself. Photomicrographs and electron micrographs should be labeled with a magnification calibration in micro or Angstrom units. A statement of the magnification should appear in the figure legend.

14. Index Terms. A list of index terms useful in constructing the annual index should be included as the last page of the manuscript.

Statistics

Wherever possible statistical probability (P) in tables, figures, and figure legends should be expressed as * P < .05, ** P < .01 and *** P < .001. For second comparisons the symbols † may be used similarly. Authors are urged to avoid unnecessary complexity and to be consistent within the manuscript. In the event of multiple comparisons within a table, footnotes, a, b, c, etc. should be used.

Abbreviations

Magnitudes of variables reported should be expressed in numerals. Most abbreviations are used without punctuation, with no distinction between singular and plural forms (e.g., 1 mg, 25 mg; 1 sec, 25 sec). The usual prefixes are to be used for multiples or submultiples of the basic units (e.g., kg, g, mg, µg, ng, pg). The following abbreviations, or their properly prefixed multiples or submultiples, may be used without definition in the text, tables and figures:

Units of mass		Units of electricity	
gram	g	volt	V
mole	mol	ampere	A
equivalent	Eq	cycles/sec	Hz
microatom	µat		
Units of concentration		Units of radioactivity	
molar (moles/liter)	M	curie	Ci
normal (Eq/liter)	N	counts per min	cpm
percent	%	disintegrations per min	dpm
		roentgen	r
Units of length or volume		Units of time	
meter	m	hour	hr or h
micron	µ	minute	min or m
Angstrom	Å	second	sec or s
liter (spell out in text)	l		
Kinetics			
dissociation constant	K_d		
Dissociation constant of			
enzyme substrate complex	K_s		
enzyme inhibitor complex	K_i		
Michaelis constant	K_m		
maximum initial velocity	V_{max}		
Miscellaneous			
degrees of temperature	°C		
gravity	g		
median doses	LD ₅₀ , ED ₅₀ , etc.		
optically isometric forms	d-, l-, dl-		
routes of drug administration	i.v., i.p., s.c., i.m.		
standard deviation	S.D.		
standard error	S.E.		

Whenever an abbreviation other than those above is to be used in a manuscript, it is to be defined in the text or in a footnote thereto, the first time it is used. Abbreviations for commonly used substances should be those recommended by the Journal of Biological Chemistry. Abbreviations for drugs may be used if properly defined on first use and if the chemical or generic name of the drug is given when the abbreviation is first used. Abbreviations may be used in the running title but not in the full title of the manuscript.

Drugs

Generic names should be used in text, tables and figures. Trade names may be mentioned in parentheses in the first text reference to the drug but should not appear in titles, figures or tables. When a trade name is used, it should be capitalized; generic or chemical names are not capitalized. The chemical nature of new drugs must be given when it is known. The form of drug used in calculations of doses (e.g., base or salt) should be indicated. When several drugs are used, it may save space to include a separate paragraph in "Methods," or a separate table or footnote, listing the relevant information about all drugs employed.

Page Charges

Authors are assessed page charges at the rate of \$30 per printed page. With the page proof, authors will receive a request for information concerning such charges. These charges will be assessed only if they involve no personal expense to the authors. Request for waiver should be addressed to the ASPET Executive Officer at the time billing is received.

The cost of a limited number of illustrations will be borne by the Journal; the cost of excessive illustrations and of colored illustrations will have to be defrayed by the authors.

After acceptance: When the field editor recommends acceptance of an article for publication, authors are encouraged to submit electronic diskettes of the final version along with the typed REVISED manuscript. The author will receive a packet of information containing copyright forms and detailed instructions pertaining to the publication of their manuscript.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with the galley proof. Please direct questions on page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814.